Twice-Rejected Melanoma Drug Gets Surprise Love From FDA Panel

by | Jul 31, 2026 | | 0 |

MedPage Today) — In the wake of a surprise FDA advisory committee vote on Thursday, the third time could be the charm for RP1 (vusolimogene oderparepvec), a melanoma drug candidate that’s already been rejected twice by the agency. Despite doubts…

Read More